American Century Companies Inc. Has $9.91 Million Position in The Clorox Company $CLX

American Century Companies Inc. cut its position in The Clorox Company (NYSE:CLX) by 26.4% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 82,556 shares of the company’s stock after selling 29,643 shares during the quarter. American Century Companies Inc. owned 0.07% of Clorox worth $9,913,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Nomura Asset Management Co. Ltd. grew its stake in Clorox by 9.0% during the second quarter. Nomura Asset Management Co. Ltd. now owns 335,514 shares of the company’s stock worth $40,285,000 after purchasing an additional 27,639 shares during the period. Simplicity Wealth LLC boosted its holdings in shares of Clorox by 157.3% during the 2nd quarter. Simplicity Wealth LLC now owns 18,316 shares of the company’s stock worth $2,199,000 after buying an additional 11,198 shares in the last quarter. Raymond James Financial Inc. grew its position in shares of Clorox by 15.6% during the 1st quarter. Raymond James Financial Inc. now owns 269,926 shares of the company’s stock worth $39,747,000 after buying an additional 36,352 shares during the period. Vise Technologies Inc. bought a new stake in shares of Clorox in the 2nd quarter valued at $328,000. Finally, Nuance Investments LLC lifted its position in shares of Clorox by 182.5% during the 2nd quarter. Nuance Investments LLC now owns 848,106 shares of the company’s stock valued at $101,832,000 after acquiring an additional 547,839 shares during the period. 78.53% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, Director Pierre R. Breber bought 4,000 shares of the firm’s stock in a transaction on Friday, November 21st. The stock was acquired at an average cost of $104.13 per share, with a total value of $416,520.00. Following the completion of the transaction, the director directly owned 13,000 shares of the company’s stock, valued at $1,353,690. This represents a 44.44% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 0.63% of the company’s stock.

Clorox Price Performance

Shares of NYSE:CLX opened at $105.04 on Friday. The company has a market capitalization of $12.81 billion, a P/E ratio of 16.49, a price-to-earnings-growth ratio of 0.52 and a beta of 0.57. The company’s 50-day moving average is $112.33 and its 200 day moving average is $120.53. The company has a debt-to-equity ratio of 18.01, a quick ratio of 0.50 and a current ratio of 0.76. The Clorox Company has a fifty-two week low of $98.20 and a fifty-two week high of $171.37.

Clorox (NYSE:CLX) last announced its quarterly earnings data on Monday, November 3rd. The company reported $0.85 EPS for the quarter, topping the consensus estimate of $0.78 by $0.07. Clorox had a net margin of 11.68% and a return on equity of 358.39%. The business had revenue of $1.43 billion for the quarter, compared to analyst estimates of $1.41 billion. During the same quarter in the previous year, the firm posted $1.86 earnings per share. The company’s revenue for the quarter was down 18.9% on a year-over-year basis. Clorox has set its FY 2026 guidance at 5.950-6.300 EPS. On average, equities research analysts forecast that The Clorox Company will post 7.15 earnings per share for the current year.

Clorox Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, February 13th. Shareholders of record on Wednesday, January 28th will be issued a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a yield of 4.7%. The ex-dividend date of this dividend is Wednesday, January 28th. Clorox’s dividend payout ratio is 77.86%.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on the stock. The Goldman Sachs Group reduced their price target on shares of Clorox from $115.00 to $110.00 and set a “sell” rating for the company in a report on Wednesday, October 1st. JPMorgan Chase & Co. cut their price objective on shares of Clorox from $127.00 to $120.00 and set a “neutral” rating on the stock in a research report on Tuesday, November 4th. Barclays decreased their target price on Clorox from $112.00 to $108.00 and set an “underweight” rating for the company in a research report on Tuesday, November 4th. TD Cowen cut their price target on Clorox from $120.00 to $117.00 and set a “hold” rating on the stock in a report on Wednesday, October 1st. Finally, Deutsche Bank Aktiengesellschaft reduced their price objective on Clorox from $128.00 to $121.00 and set a “hold” rating for the company in a research note on Tuesday, November 4th. One investment analyst has rated the stock with a Buy rating, thirteen have given a Hold rating and four have assigned a Sell rating to the stock. According to MarketBeat.com, Clorox presently has a consensus rating of “Reduce” and an average price target of $125.69.

Clorox Profile

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.